Verastem Inc

Verastem, Inc. leads biopharma innovation targeting RAF, MEK, and FAK pathways, aiming to transform cancer therapy and improve patient outcomes.

Verastem, a development-stage biopharma firm, targets RAF, MEK and FAK pathways to develop breakthrough cancer therapies, aiming to reshape oncology treatment.

Verastem, Inc. is a development-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies through its research and development of treatments targeting critical cancer pathways.

Verastem Inc. has received accelerated FDA approval for its innovative ovarian cancer therapy, AVMAPKI FAKZYNJA, marking a significant milestone in the company’s mission to advance new medicines for cancer treatment.